Table 4.
Prognostic factors that affect EFS and OS (univariate analysis)
| Risk factor | Event‐free survival | Overall survival | ||
|---|---|---|---|---|
| RR (95% CI) | P | RR (95% CI) | P | |
| Age (>60 vs ≤60 y) | 2.888 (1.916‐4.353) | <0.001 | 2.966 (1.958‐4.491) | <0.001 |
| Sex (female vs male) | 0.964 (0.646‐1.437) | 0.857 | 1.017 (0.681‐1.519) | 0.935 |
| Ann Arbor stage (III‐IV vs I‐II) | 4.106 (2.664‐6.328) | <0.001 | 4.129 (2.672‐6.380) | <0.001 |
| Extranodal involvement (≥2 vs <2) | 3.076 (2.002‐4.725) | <0.001 | 3.125 (2.034‐4.801) | <0.001 |
| LDH level (evaluated vs normal) | 1.962 (1.502‐2.564) | <0.001 | 2.079 (1.575‐2.744) | <0.001 |
| ECOG PS (≥2 vs <2) | 2.673 (1.737‐4.114) | <0.001 | 2.592 (1.682‐3.995) | <0.001 |
| IPI (3‐5 vs 0‐2) | 4.509 (2.891‐7.032) | <0.001 | 2.390 (1.471‐3.882) | <0.001 |
| GC phenotype (non‐GCB vs GCB) | 2.236 (1.388‐3.600) | 0.001 | 3.080 (1.740‐5.452) | <0.001 |
| Treatment (R‐CHOP vs CHOP) | 0.759 (0.501‐1.149) | 0.192 | 0.767 (0.506‐1.161) | 0.209 |
| Ki‐67 (≥80% vs <80%) | 1.691 (1.129‐2.552) | 0.011 | 1.625 (1.085‐2.443) | 0.018 |
| CD5 (positive vs negative) | 3.300 (1.892‐5.755) | <0.001 | 3.696 (2.102‐6.499) | <0.001 |
| CD43 (positive vs negative) | 3.180 (2.095‐4.829) | <0.001 | 2.891 (1.916‐4.362) | <0.001 |
| CD5+CD43+ vs others | 7.707 (3.742‐15.872) | <0.001 | 6.250 (3.057‐12.778) | <0.001 |
CI, confidence interval; RR, relative risk; LDH, lactic dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; GC, germinal center; GCB, germinal center B cell.